Adenosine Deaminase in Pleural Effusion and Its Relationship with Clinical Parameters in Patients with Malignant Pleural Mesothelioma
Adenosine Deaminase in Pleural Effusion and Its Relationship with Clinical Parameters in Patients with Malignant Pleural Mesothelioma
复制标题
DOI：
10.1080/07357907.2020.1776313
复制
发表时间：
2020-06-12
影响因子：
2.4
通讯作者：
Kijima, Takashi
中科院分区：
文献类型：
--
作者：
Nakajima, Yasuhiro;Kuribayashi, Kozo;Kijima, Takashi
胸腔积液腺苷脱氨酶（ADA）水平升高，在各种疾病。我们调查了恶性胸膜间皮瘤（MPM）、肺癌（LC）和良性疾病（包括结核性胸膜炎）患者胸腔积液ADA水平是否不同。我们从2002年2月至2013年7月检查了329例患者。MPM患者131例，ADA水平为32.29 IU/L，LC患者117例，ADA水平为21.12 IU/L，良性疾病患者54例，ADA水平为20.98 IU/L。MPM与良性疾病患者胸水ADA水平差异有显著性。MPM患者胸腔积液ADA水平显著升高。
Pleural effusion adenosine deaminase (ADA) levels are elevated in various diseases. We investigated whether pleural effusion ADA levels differ among patients with malignant pleural mesothelioma (MPM), lung cancer (LC), and benign diseases, including tuberculous pleurisy. We examined 329 patients from February 2002 to July 2013. There were 131 MPM cases with ADA levels of 32.29 IU/L; 117 LC cases with ADA levels of 21.12 IU/L; 54 benign disease cases with ADA levels of 20.98 IU/L. A significant difference existed in pleural effusion ADA levels between MPM and benign disease patients. Pleural effusion ADA levels were significantly higher in MPM patients.